AGIO Agios Pharmaceuticals, Inc.

54.13
+1  (2%)
Previous Close 52.92
Open 53.03
Price To book 6.23
Market Cap 2.29B
Shares 42,234,000
Volume 409,416
Short Ratio 12.86
Av. Daily Volume 576,028

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

NDA filing due by end of 2017.
AG-120
IDH1m Relapsed/Refractory AML - cancer
Phase 2 first data released at EHA meeting June 2016. Updated data due 2H 2017. Pivotal trial design update due 3Q 2017.
AG-348
Pyruvate kinase deficiency
Phase 3 to be initiated 1H 2017
AG-120 and VIDAZA
Frontline Acute myeloid leukemia (AML) harboring an IDH1 mutation - cancer
Global Phase 3 study for AG-221 initiated October 2015. Continue to enrol through 2016
AG-221 - IDHENTIFY
Refractory Acute myeloid leukemia (AML) - cancer
PDUFA date August 30, 2017 under priority review.
Enasidenib (AG-221)
Advanced hematologic malignancies with an IDH2 mutation
Phase 2 initiated December 2016.
AG-120
IDH1 mutant positive cholangiocarcinoma - cancer

Latest News

  1. 4 Health Care Charts Signaling Buys: Pfizer, Amgen Included
  2. Why Is Agios (AGIO) Up 8.5% Since the Last Earnings Report?
  3. AGIOS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  4. Agios Announces MTAP Pathway Research Program as Development Program and Development Candidate Under Master Research and Collaboration Agreement with Celgene
  5. Biotechs Among 5 Stocks Setting Up for Major Breakouts
  6. ​Agios CEO touts path from 'a blank piece of paper' to cusp of drug approval
  7. FDA Accepts New Drug Application and Grants Priority Review for Enasidenib in Relapsed or Refractory AML with an IDH2 Mutation
  8. Agios to Present at the Cowen and Company 37th Annual Health Care Conference on Monday, March 6, 2017
  9. AGIOS PHARMACEUTICALS INC Financials
  10. Agios Pharmaceuticals, Inc. :AGIO-US: Earnings Analysis: Q4, 2016 By the Numbers : February 21, 2017
  11. Agios Pharmaceuticals 4Q Loss $1.48 Per Share
  12. Agios Pharmaceuticals, Inc. :AGIO-US: Earnings Analysis: 2016 By the Numbers : February 17, 2017
  13. Agios Pharma (AGIO) Q4 Loss Narrower than Expected; Stock Up
  14. Edited Transcript of AGIO earnings conference call or presentation 16-Feb-17 1:00pm GMT
  15. Agios (AGIO) Q4 Loss Narrower than Expected; Revenues Up Y/Y
  16. Agios Pharmaceuticals Inc Earnings Call scheduled for 8:00 am ET today
  17. AGIOS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
  18. Agios Pharmaceuticals reports 4Q loss
  19. Agios Pharmaceuticals reports 4Q loss
  20. Q4 2016 Agios Pharmaceuticals Inc Earnings Release - Before Market Open